Merck and Moderna Announce 42 Percent Drop in Melanoma Risk With Personalized mRNA Vaccine
Late-stage trial data released in Madrid shows the tailored vaccine significantly lowers the chance of cancer returning or causing death compared to standard therapy alone.
By Layla Petrov ·
Personalized mRNA vaccines for melanoma have cut the risk of death or recurrence by 42 percent compared to standard care, Merck and Moderna announced today. The late-stage trial results mark a major breakthrough in treating the deadliest form of skin cancer and signal a potential shift in how oncologists approach tumor-targeted therapies. The pharmaceutical partners have already begun discussions with regulatory bodies to push for approval of the new treatment.
Moderna CEO Stéphane Bancel stated that the company has long believed mRNA technology could enable cancer treatments uniquely matched to each patient's tumor. He described the trial results as a defining moment for that vision, noting that they show what is possible when the production of medicines is rethought. Bancel added that the findings reinforce the conviction that mRNA has the potential to fundamentally change cancer treatment.
The companies originally planned to present the detailed data at a scientific conference but released the top-line results earlier than scheduled. An oncology news site reported the findings ahead of time, breaking the embargo. The full data has been accepted for publication in the New England Journal of Medicine. The announcement coincides with the European Society of Medical Oncology conference, which is currently underway in Madrid, Spain.
In August, Merck and Moderna reported that the vaccine had succeeded in the trial but withheld specific details until the data could be presented at the conference. The presentation was set for Saturday, but the early leak forced the companies to share the headline numbers now. This move highlights the intense interest in the results and the fast pace of developments in personalized medicine.
The Phase 3 trial involved 1,137 patients with stage IIB to IV melanoma. All participants had undergone surgery to remove the cancer before entering the study. Patients were randomized in a two-to-one ratio to receive either the combination treatment or the standard treatment alone. The standard arm included Merck's established monoclonal antibody cancer treatment, Keytruda.
The combination therapy paired the personalized mRNA vaccine with the standard Keytruda regimen. The results show that adding the vaccine significantly improved outcomes over using Keytruda by itself. This success bolsters hope that individualized cancer-targeting medicines and mRNA vaccines offer a new paradigm for cancer therapies beyond melanoma.
Regulatory authorities are now engaged in the approval process following the announcement. The companies aim to move quickly on the path to market given the magnitude of the benefit seen in the trial. The data represents a significant advance in melanoma treatment and provides a strong foundation for future studies in other cancer types.
The early release of the data underscores the competitive and scientific environment surrounding mRNA cancer vaccines. The full paper in the New England Journal of Medicine will provide further details on the trial methodology and safety profile. For now, the 42 percent reduction in risk stands as the key metric driving the next phase of development.
Patients and healthcare providers are watching closely as the approval process moves forward. The collaboration between Merck and Moderna has produced one of the most significant results in recent cancer research. The next steps involve finalizing the regulatory filings and preparing for broader clinical implementation.
